Version 1
: Received: 3 November 2023 / Approved: 6 November 2023 / Online: 6 November 2023 (08:13:49 CET)
How to cite:
Fahimi, B.; Beikmohammadi, S. The Complex Interplay Between SGLT2 Inhibitors and Atrial Fibrillation: Mechanisms and Clinical Implications. Preprints2023, 2023110295. https://doi.org/10.20944/preprints202311.0295.v1
Fahimi, B.; Beikmohammadi, S. The Complex Interplay Between SGLT2 Inhibitors and Atrial Fibrillation: Mechanisms and Clinical Implications. Preprints 2023, 2023110295. https://doi.org/10.20944/preprints202311.0295.v1
Fahimi, B.; Beikmohammadi, S. The Complex Interplay Between SGLT2 Inhibitors and Atrial Fibrillation: Mechanisms and Clinical Implications. Preprints2023, 2023110295. https://doi.org/10.20944/preprints202311.0295.v1
APA Style
Fahimi, B., & Beikmohammadi, S. (2023). The Complex Interplay Between SGLT2 Inhibitors and Atrial Fibrillation: Mechanisms and Clinical Implications. Preprints. https://doi.org/10.20944/preprints202311.0295.v1
Chicago/Turabian Style
Fahimi, B. and Somayeh Beikmohammadi. 2023 "The Complex Interplay Between SGLT2 Inhibitors and Atrial Fibrillation: Mechanisms and Clinical Implications" Preprints. https://doi.org/10.20944/preprints202311.0295.v1
Abstract
This comprehensive review delves into the intricate relationship between Sodium-GlucoseCo-Transporter 2 (SGLT2) inhibitors and AF, highlighting the multifaceted actions of thesedrugs and their significant cardiovascular benefits. Mechanisms: SGLT2 inhibitors inducesubstantial hemodynamic changes, impacting blood pressure, adipose tissue function, andinflammation. They enhance glycemic control while potentially reducing oxidative stress andinflammation, and they modulate atrial electrophysiology, collectively contributing to the reductionof AF risk. Clinical Evidence: This review synthesizes a wealth of clinical evidence,drawing from observational studies and randomized controlled trials, consistently demonstratinga correlation between SGLT2 inhibitors, particularly dapagliflozin and empagliflozin, anda decreased risk of AF. This protective effect is most pronounced in patients with type 2 diabetesand heart failure, underscoring their potential as therapeutic agents for high-risk populations.Potential Benefits: SGLT2 inhibitors offer a spectrum of potential benefits, includingsubstantial reductions in AF risk, particularly in patients with type 2 diabetes and heart failure.These drugs have consistently demonstrated benefits in reducing heart failure hospitalizations,cardiovascular mortality, and stroke risk, which indirectly contribute to better AF management.Furthermore, SGLT2 inhibitors exhibit renoprotective properties by slowing theprogression of chronic kidney disease and reducing albuminuria, offering substantial benefitsfor AF patients with comorbid kidney disease. Metabolic improvements involving weight loss,blood pressure reduction, and favorable changes in lipid profiles contribute to enhanced cardiovascular health and reduced AF risk. Originally designed for diabetes management, thesemedications offer a holistic approach to AF risk reduction, particularly in patients with type 2diabetes and heart failure.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
